L
Lisa A. Varughese
Researcher at University of Pennsylvania
Publications - 9
Citations - 62
Lisa A. Varughese is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 4 publications receiving 7 citations.
Papers
More filters
Journal ArticleDOI
Real-world integration of genomic data into the electronic health record: the PennChart Genomics Initiative.
Kelsey S. Lau-Min,Stephanie Byers Asher,Jessica A. Chen,Susan M. Domchek,Michael Feldman,Steven Joffe,Jeffrey Landgraf,Virginia Speare,Lisa A. Varughese,Sony Tuteja,Christine VanZandbergen,Marylyn D. Ritchie,Katherine L. Nathanson +12 more
Journal ArticleDOI
Preemptive pharmacogenetic testing to guide chemotherapy dosing in patients with gastrointestinal malignancies: a qualitative study of barriers to implementation
Kelsey S. Lau-Min,Lisa A. Varughese,Maria N. Nelson,Christine Cambareri,Nandi J. Reddy,Randall A. Oyer,Ursina R. Teitelbaum,Sony Tuteja +7 more
TL;DR: This paper conducted a qualitative study of oncology clinicians to identify barriers to using preemptive pharmacogenetic (PGx) testing to guide chemotherapy dosing in patients with gastrointestinal malignancies.
Journal ArticleDOI
Preemptive pharmacogenetic testing to guide chemotherapy dosing in patients with gastrointestinal malignancies: a qualitative study of barriers to implementation
Kelsey S. Lau-Min,Lisa A. Varughese,Maria N. Nelson,Christine Cambareri,Nandi J. Reddy,Randall A. Oyer,Ursina R. Teitelbaum,Sony Tuteja +7 more
TL;DR: The authors conducted a qualitative study of oncology clinicians to identify barriers to using preemptive pharmacogenetic (PGx) testing to guide chemotherapy dosing in patients with gastrointestinal malignancies.
Journal ArticleDOI
DPYD and UGT1A1 Pharmacogenetic Testing in Patients with Gastrointestinal Malignancies: An Overview of the Evidence and Considerations for Clinical Implementation
Lisa A. Varughese,Kelsey S. Lau-Min,Christine Cambareri,Nevena Damjanov,Ryan Massa,Nandi J. Reddy,Randall A. Oyer,Ursina R. Teitelbaum,Sony Tuteja +8 more
TL;DR: The PGx profiles of drug‐gene pairs with potential impact in GI malignancy therapy – DPYD‐5‐fluorouracil/capecitabine and UGT1A1‐irinotecan – and the available clinical evidence of their roles in reducing severe adverse events are discussed.
Journal ArticleDOI
Implementing Pharmacogenetic Testing in Gastrointestinal Cancers (IMPACT-GI): Study Protocol for a Pragmatic Implementation Trial for Establishing DPYD and UGT1A1 Screening to Guide Chemotherapy Dosing
Lisa A. Varughese,Madhuri Bhupathiraju,Glenda Hoffecker,Shannon Terek,Margaret Harr,Hakon Hakonarson,Christine Cambareri,Jessica Marini,J. M. Landgraf,Jinbo Chen,Genevieve P. Kanter,Kelsey S. Lau-Min,Ryan Massa,Nevena Damjanov,Nandi J. Reddy,Randall A. Oyer,Ursina R. Teitelbaum,Sony Tuteja +17 more
TL;DR: It is hypothesized that the availability of a rapid turnaround PGx test with specific dosing recommendations will increasePGx test utilization to guide pharmacotherapy decisions and improve patient safety outcomes and may help other institutions interested in implementing PGx testing in oncology care.